Mylan’s Payments to Medicaid for EpiPen Queried by Lawmakers
- Medicaid may have been grossly underpaid, the lawmakers say
- Mylan shares fall after letter to drugmaker made public
This article is for subscribers only.
Two top Democratic lawmakers asked for information about how Mylan NV may have grossly underpaid rebates to a government health program for its EpiPen allergy shot for almost two decades, adding to the growing number of inquiries about the drugmaker’s pricing practices.
Senator Ron Wyden of Oregon and House Representative Frank Pallone from New Jersey sent a letter to Health and Human Services Secretary Sylvia Mathews Burwell Friday, asking for more details about the drug’s classification and rebate obligations under the Medicaid health program for the poor.